HERITAGE: a phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus herceptin von Rugo, H, Barve, A, Waller, C, Bronchud, M.H, Herson, J, Yuan, J, Manikhas, A, Bondarenko, I, Mukhametshina, G, Nemsadze, G, Parra, J, Abesamis Tiambeng, M.L, Baramidze, K, Akewanlop, C, Vynnychenko, I, Sriuranpong, V, Mamillapalli, G, Ray, S, Yanez Ruiz, E.P, Pennella, E

Volltext

16P Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment von Lai, J-I., Antill, Y., Jung, K.H., Shimizu, C., Abesamis Tiambeng, M.L., Tseng, L-M., Tan, E.M., Qu, S., Spiteri, C., Ihm, S.Y., Hsu, D.

Volltext

255 - HERITAGE: a phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus herceptin von Rugo, H., Barve, A., Waller, C., Bronchud, M.H., Herson, J., Yuan, J., Manikhas, A., Bondarenko, I., Mukhametshina, G., Nemsadze, G., Parra, J., Abesamis Tiambeng, M.L., Baramidze, K., Akewanlop, C., Vynnychenko, I., Sriuranpong, V., Mamillapalli, G., Ray, S., Yanez Ruiz, E.P., Pennella, E.

Volltext